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The pathophysiology of primary open-angle glaucoma is still largely unknown, although a joint contribution of vascular,
biomechanical, and biochemical factors is widely acknowledged. Since glaucoma is a leading cause of irreversible blindness
worldwide, exploring its underlying pathophysiological mechanisms is extremely important and challenging. Evidence from recent
studies appears supportive of the hypothesis that a “glymphatic system” exists in the eye and optic nerve, analogous to the described
“glymphatic system” in the brain. As discussed in the present paper, elucidation of a glymphatic clearance pathway in the eye could
provide a new unifying hypothesis of glaucoma that can incorporate many aspects of the vascular, biomechanical, and biochemical
theories of the disease. It should be stressed, however, that the few research data currently available cannot be considered as proof
of the existence of an “ocular glymphatic system” and that much more studies are needed to validate this possibility. Even though
nothing conclusive can yet be said, the recent reports suggesting a paravascular transport system in the eye and optic nerve are
encouraging and, if confirmed, may offer new perspectives for the development of novel diagnostic and therapeutic strategies for
this devastating disorder.
1. Introduction
Glaucoma is one of the leading causes of irreversible
blindness worldwide [1–3]. Primary open-angle glaucoma
(POAG), the most common type, is characterized by the
progressive degeneration of retinal ganglion cells (RGCs)
and their axons in the optic nerve, resulting in structural
changes in the optic nerve head and corresponding visual
field defects [4]. The lamina cribrosa, a sieve-like structure
in the posterior part of the sclera that allows passage of
the RGC axons and central retinal vessels, seems to be the
primary site of axonal injury in glaucoma [5]. Although the
underlying pathophysiology of glaucomatous optic neuropa-
thy (GON) remains elusive, elevated intraocular pressure
(IOP) is considered the most important modifiable risk
factor [6]. However, in a significant proportion of patients
designated normal-tension glaucoma (NTG), the disease
occurs in spite of normal IOP and thus other risk factors




Volume 2017, Article ID 5123148, 7 pages
https://doi.org/10.1155/2017/5123148
2 BioMed Research International
Although the mechanism(s) underlying optic nerve
injury in glaucoma remain poorly understood, at least three
theories have been suggested, including the vascular, biome-
chanical, and biochemical theories. The vascular theory of
glaucoma considers GON as a consequence of insufficient
blood supply due to increased IOP and/or other risk factors
reducing ocular blood flow [7]. The mechanical theory
suggests that GON may result from increased IOP leading
to regions of high shear stress and strain in the lamina
cribrosa [7]. Over the past few years, there has beenmounting
evidence in the literature on the possible role of biochemical
mechanisms leading to glaucomatous neurodegeneration [8].
These biochemical mechanisms include the role of excitatory
amino acids, caspases, protein kinases, oxygen free radicals,
nitric oxide, tumor necrosis factor-alpha, neurotrophins, and
metalloproteins [8].
An intriguing finding of several studies is that intracranial
pressure (ICP) is lower in patients with POAG and NTG [10–
12], and a growing body of evidence indicates that glaucoma
is a condition that develops from a mismatch in pressures
across the lamina cribrosa. The optic nerve, a white matter
tract of the central nervous system (CNS), is ensheathed in all
threemeningeal layers and surrounded by cerebrospinal fluid
(CSF) in the subarachnoid space (SAS) with a pressure equiv-
alent to ICP [13]. The movement of CSF along the outside
of the optic nerve is well known. When tracers are injected
into the cisternamagna or lateral ventricles, they are detected
in/around the optic nerve [14, 15]. Thus, in addition to IOP,
the optic nerve is exposed to the ICP [6].The lamina cribrosa
separates these two pressurized regions [6]. It forms a pres-
sure barrier between the high-pressure compartment of the
intraocular space and the low-pressure compartment of the
retrobulbar CSF space [16].The forces experienced at the level
of the optic nerve head are influenced by both IOP and ICP.
Thedifference between the posteriorly directed IOP and ante-
riorly directed ICP across the lamina cribrosa is known as the
trans-lamina cribrosa pressure difference (TLCPD) [6]. The
pressure drop that occurs across the lamina cribrosa (IOP-
ICP) increases with elevation of IOP or reduction of ICP [6].
Recent insights intoCSF biology have revealed the impor-
tance of the so-called “glymphatic system” in the clearance
of potentially neurotoxic waste products, including amyloid-
𝛽 (A𝛽), from the brain via paravascular spaces surrounding
cerebral blood vessels [17]. Interestingly, new research now
lends support to the hypothesis that a similar system is
present in the eye and optic nerve [9]. The discovery of
such an “ocular glymphatic system” may be of particular
importance for the understanding of the pathophysiology of
POAG, given that studies in glaucomatous animal models
have shown that A𝛽 is a likely mediator of pressure-induced
RGC death [18]. As discussed in the present paper, an intrigu-
ing possibility is that the glymphatic hypothesis of glaucoma
may integrate many aspects of the above-noted vascular,
biomechanical, and biochemical theories of the disease.
2. Discussion
2.1. The Brain and the Eye May Have a Similar Glymphatic
Clearance Pathway. A novel hypothesis of glaucoma recently
proposed by our group is that the disease may result from
a dysfunction of the so-called “glymphatic system” [13]. The
glymphatic system was first described by Iliff et al. [17] in
2012. The authors defined for the first time a brain-wide
network of paravascular pathways in mice, along which a
large proportion of subarachnoid CSF circulates through
the brain parenchyma, facilitating the clearance of intersti-
tial solutes, including A𝛽, from the brain [17]. CSF enters
the brain along para-arterial channels for exchange with
interstitial fluid (ISF), which is in turn cleared from the
brain along paravenous pathways for ultimate clearance via
cervical lymphatic vessels [17, 19]. From the SAS, CSF is
driven into the Virchow-Robin spaces by a combination
of arterial pulsatility, respiration, slow vasomotion, and
CSF pressure gradients [19, 20]. The subsequent transport
of CSF into the dense and complex brain parenchyma is
facilitated by aquaporin-4 (AQP4) water channels which are
expressed in a highly polarized manner in astrocytic end-feet
ensheathing the cerebral vasculature [19]. AQP4 is essential
for water movement across astrocyte cell membranes. A
recent study on meningothelial cells that cover the SAS of
the optic nerve (including the trabeculae and septa) also
demonstrated the presence of AQP4 in human optic nerve
sections [21]. Besides removal of metabolic waste products,
the glymphatic system may also function to help distribute
non-waste compounds, such, such as glucose, lipids, amino
acids, and neurotransmitters related to volume transmission,
in the brain [19]. Recent analysis shows that the glymphatic
system is highly active during sleep and is largely disengaged
during wakefulness [19]. It should be noted that while the
glymphatic concept assumes transport from the SAS into
the parenchyma along periarterial pathways, other studies
suggest that the periarterial flow provides a drainage out of
the parenchyma [22, 23]. Moreover, the possibility has been
raised that the paravascular CSF fluxes observed in previous
studies [17, 20] could represent artefacts of changes in ICP
resulting from CSF tracer infusion [24]. Obviously, further
studies are needed to substantiate the functional significance
of the glymphatic concept. Also, studies in other species are
warranted. Elucidation of the potential role of the glymphatic
system in the human brain is extremely challenging since
dysfunction of this systemmay be an important contributing
factor in neurodegenerative diseases such as Alzheimer’s
disease (AD).
Intriguingly, recent reports presented at the ARVO 2016
Annual Meeting together with preliminary data from our
own postmortem study [9] suggest that a similar paravascular
clearance system is present in the human optic nerve and
retina. In a postmortem study to investigate the possibility
of a paravascular fluid circulation, or at least paravascular
spaces, in the human optic nerve, we examined cross-sections
of human optic nerves by light microscopy after administer-
ing India ink by bolus injection into the SAS of the optic nerve
(work in progress). The results demonstrated accumulation
of India ink in paravascular spaces around the central retinal
artery and vein, whereas the lumens of these vessels remained
unlabelled [9]. The deposits were located between collagen
fiber bundles lining a slit-like space [9]. In addition, in their
report presented at the ARVO 2016 Annual Meeting, Hu and
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colleagues [25] provided evidence for a glymphatic system in
human, non-human primate, rat, and mouse retina. Retinas
were examined using multimarker immunohistochemistry.
An AQP4+ glial network ensheathed the entire retinal vascu-
lar system, including between blood vessels, and the authors
concluded that this may be the anatomical correlate of a
retinal glymphatic system. In yet another report presented at
the ARVO 2016 Annual Meeting, Lo¨ffler and colleagues [26]
provided support for lymphatic structures in ADmice retinas
similar to the glymphatic system in the brain. The authors
investigated possible clearance pathways for A𝛽 in an AD
mouse model (SwAPP/Psen1d9). AD mice retinas exhibited
enhanced amyloid precursor protein (APP) production with
increased amyloid processing and A𝛽 accumulation versus
wild-type mice. Retinal A𝛽 plaques were much smaller than
in brain. A𝛽 plaques were located around and in retinal blood
vessels. Podoplanin (lymphatic vessel marker) colocalized
with A𝛽 and was increased in AD retinas versus wild-type
mice, indicating lymphatic-like vessels in the retina. The
authors concluded that A𝛽 clearance from the retina may
occur via lymphatic structures analogous to the described
glymphatic system of the brain. These structures appear
enhanced in AD.
Intriguingly, in 2015, two independent studies by
Aspelund et al. [27] and Louveau et al. [28] reported the
presence of dura-associated lymphatic vessels in the brain.
These two studies further suggested a connection between the
newly identifiedmeningeal lymphatic vessels and the recently
discovered glymphatic system. Interestingly, lymphatics in
the dura mater of the human optic nerve have previously
been described by Gausas et al. [29] and Killer et al. [30].
These findings together with our postmortem observations
[9] suggest at least the possibility that a connection may
exist between the paravascular fluid circulation and the
meningeal lymphatic system in the optic nerve, such as that
very recently described between the glymphatic system and
the dura-associated lymphatic vessels in the brain. In an
editorial discussing our recent publication [9], An et al. [31]
concluded by saying that “the linkage between these putative
glymphatic systems and the now recognized true lymphatic
vessels seen at the termination of the optic nerve SAS around
the optic disc is yet to be clarified and is almost certainly
going to provide a source for interesting and useful research
in the future.”
2.2. Glaucoma Considered as an Imbalance between Pro-
duction and Clearance of Neurotoxins, Including Amyloid-𝛽.
Considerable evidence indicates that A𝛽 may be implicated
in the development of axonal damage and RGC apoptosis
in glaucoma [18, 32–34], suggesting a possible link with
AD. Previous findings showed that there is IOP-sensitive
increase in A𝛽 in glaucoma [18, 32–34]. McKinnon et al.
[32] reported that rat RGCs subjected to chronic elevation
of IOP exhibit caspase-3-mediated abnormal processing of
APP with increased expression of A𝛽. This suggested a new
hypothesis for RGC death in glaucoma involving chronic
A𝛽 neurotoxicity, mimicking AD at the molecular level [33].
Activation of caspases and abnormal APP processing, which
includes production of A𝛽, are also important events in
AD [32]. Guo et al. [18] provided further evidence that
A𝛽 is a likely mediator of pressure-induced RGC death. In
a rat model mimicking chronic ocular hypertension, the
authors found that A𝛽 colocalized with apoptotic RGCs [18].
They also demonstrated in vivo that A𝛽 induced significant
RGC apoptosis [18]. The authors further provided evidence
that targeting A𝛽 and blocking its effects with combination
therapy may represent an effective treatment strategy in
glaucoma [18]. By manipulating the A𝛽 pathway, the authors
investigated three different approaches to targeting A𝛽 in
experimental glaucoma and their combination effects: (i)
reduction of A𝛽 formation by a 𝛽-secretase inhibitor; (ii)
clearance of A𝛽 deposition by an anti-A𝛽 antibody; and
(iii) inhibition of A𝛽 aggregation and neurotoxic effects with
Congo red [18].The authors showed that combined treatment
(triple therapy) wasmore effective than either single- or dual-
agent therapy [18]. Recently, in a study using monkeys with
experimental glaucoma, Ito et al. [34] found time-dependent
expressions and localization of A𝛽 in the retina as well as in
the optic nerve head after chronic IOP elevation.
The retina is an extension of the CNS, sharing embry-
ological, anatomical, and physiological similarities to the
brain [35], and therefore, it seems likely, as suggested in
the above-mentioned ARVO reports, that the branches of
the central retinal vessels in the retina are also surrounded
by paravascular spaces with the same properties as the
paravascular spaces in the brain. Furthermore, given that A𝛽
has been reported to increase by chronic elevation of IOP
in glaucomatous animal models and to cause RGC death
[18, 32–34], the above-noted findings in the eye presented at
ARVO raise the possibility that the clearance of IOP-induced
A𝛽 from the retina may occur via glymphatic structures
analogous to the described glymphatic system of the brain
and that glaucoma, just like AD, may occur when there is an
imbalance between production and clearance of neurotoxins,
including A𝛽 [13, 36].
2.3.The Lamina Cribrosa as a Potential Choke Point for Glym-
phatic Flow between the Optic Nerve and Retina. It should
be stressed that the few research data currently available,
although encouraging, cannot be considered as proof that a
“glymphatic system” exists in the eye and that much more
studies are needed to validate this possibility. If evidence fur-
ther confirms the existence of an “ocular glymphatic system,”
it would be interesting to further investigate whether a “par-
avascular communication” exists between the surroundings
of the retinal vascular system and the surroundings of the
central retinal vessels in the optic nerve. Such a paravascular
“retino-orbital” continuity has previously been suggested [37]
andwould include a para-arterial CSF influx route around the
central retinal artery to enter the paravascular spaces of the
retina, followedby a paravenous clearance efflux route around
the central retinal vein (Figures 1(a) and 1(b)) [9]. From this
point of view, the lamina cribrosa might play a critical role in
the paravascular flow between the optic nerve and retina that
can cause blockage of this flow with decreased elimination
of neurotoxic substances, such as A𝛽, and subsequent GON.
Histological studies in humans and animals have shown that
eyes with glaucoma or elevated IOP often have deformities

















Figure 1: Schematic depiction of our hypothesis. Cerebrospinal fluid enters the paravascular spaces in the retina along a para-arterial influx
route around the central retinal artery (a), followed by a paravenous clearance efflux route around the central retinal vein (b) (Figures 1(a)
and 1(b) reproduced from [9]).
of the lamina cribrosa such as posterior laminar displace-
ment, laminar thinning, pore deformities, and focal laminar
defects [38]. In glaucomatous eyes, alterations in the lamina
cribrosa structure may be sufficient to mechanically interfere
with glymphatic flow through it. Furthermore, as discussed
below, paravascular flow through the lamina cribrosa may
be restricted in proportion to the amount of the trans-
lamina cribrosa pressure gradient (IOP-ICP/thickness of the
lamina cribrosa), and also vascular factors may disturb the
physiologic glymphatic flow through it.
2.4. Vascular Pulsatility and Cerebrospinal Fluid Pressure as
Influencing Factors for Ocular Glymphatic Clearance. Eluci-
dation of a glymphatic clearance pathway in the eye could
provide a new unifying hypothesis of glaucoma that can
incorporate many aspects of the vascular, biomechanical,
and biochemical theories of the disease. Indeed, vascular
and mechanical factors may lead to changes in paravascular
transport at the site of the lamina cribrosa, influencing glym-
phatic clearance of toxic substances from the retina. As noted
above, cerebral arterial pulsation is a key driving force for
glymphatic flow [20]. Analogous to the vascular pulsations in
the brain, central retinal artery pulsation could be a key driver
of para-arterial CSF influx into the retina. In the eye, high
pulsatility efficiency of the central retinal artery may be of
paramount importance because the para-arterial CSF influx
from the optic nerve to the retina is supposed to occur against
the trans-lamina cribrosa pressure gradient. Normally, IOP is
higher than ICP [6]. An increase in IOP, a decrease in ICP, or a
decrease in the thickness of the lamina cribrosa may increase
the pressure barrier against which paravascular flow from the
optic nerve to the retina needs to occur. Patients with low ICP
and/or high trans-lamina cribrosa pressure barriers and/or
central retinal artery pulsatility inefficiency may therefore be
more likely to develop glymphatic stasis at the site of the
lamina cribrosa, leading to reduced neurotoxin clearance and
subsequent GON. Another potentially important aspect may
be the dynamics of the pressure changes. A previous study by
Morgan et al. [39] investigated the timing of retinal venous
pulsation in relation to IOP and ICP pulses. The authors
demonstrated a difference in the phasing of the IOP curve
and the phasing of the ICP curve with respect to the cardiac
cycle, with the ICP curve reaching its height earlier than the
IOP curve [39, 40]. In full agreement with these findings,
Jonas et al. [40] wondered whether these physiological short-
term changes in the TLCPD, potentially even resulting in
short-term reversals of the TLCPD, may physiologically be
needed to allow the retrograde axoplasmic flow entering the
eye. Similarly, we believe that this swinging of TLCPD may
also be important for paravascular CSF influx from the optic
nerve to the retina.
Interestingly, as mentioned above, recent research sug-
gests that, along with IOP, alterations in ICP may be involved
in glaucoma. A growing body of evidence indicates that ICP
is lower in patients with POAG and NTG [10–12], and a low
ICP gains interest as a new risk factor for glaucoma. This
is in line with the present hypothesis. Indeed, if the ICP is
too low, fluid flow from the paravascular spaces in the optic
nerve to the paravascular spaces in the retina may decline or
stop, given that this paravascular flow must cross the trans-
lamina cribrosa pressure barrier. It is interesting to note that
ICP was found to be lower in NTG patients than in high-
tension glaucoma patients [11, 12]. In high-tension glaucoma,
IOP-induced generation of toxins might predominate and
evenmild impairment of glymphatic pathway functionmight
result in glaucomatous optic nerve damage. In NTG, reduced
clearance of toxic substances might predominate as a result
of glymphatic stasis. Importantly, a previous study in an
experimental animal model provided evidence for a possible
toxic effect of stagnant CSF on the optic nerve [41]. It was
postulated that an accumulation of biologically highly active
substances such as lipocalin-like prostaglandin D synthase
(L-PGDS), a protein present in the CSF, could exercise a
harmful effect on axons and mitochondria of the optic nerve
[41]. The highest concentration of mitochondria is located
right behind the lamina cribrosa in nonmyelinated axons
[41]. The main function of mitochondria is the production
of adenosine triphosphate, which is essential for cell survival
[42]. Given that the unmyelinated optic nerve has a high rela-
tive demand for mitochondrial enzyme activity, the immedi-
ate retrobulbar portion of the optic nerve may be particularly
vulnerable to toxic effects [41]. Given that astrocytes play a
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critical role in maintaining the integrity of axon function in
the central nervous system and specifically in the optic nerve,
Xin et al. [43] investigated the biochemical effects of L-PGDS
on the proliferation of astrocytes and on the production of
adenosine triphosphate by astrocyte mitochondria in an in
vitromodel.The authors demonstrated an inhibitory effect of
L-PGDS on both proliferation of astrocytes and production
of astrocyte adenosine triphosphate [43]. Obviously, L-PGDS
is only one of many CSF components with biological activity
and other substances could also be harmful.
It is also interesting to note that systemic arterial stiffness,
which can occur as a consequence of arteriosclerosis, has
been reported to be associated with POAG andNTG [44, 45].
Mroczkowska et al. [44] found systemic arterial stiffness
assessed by pulse wave analysis to be comparably increased in
early-stage POAG andNTGpatients comparedwith controls.
Shim et al. [45] investigated the role of systemic arterial
stiffness in glaucoma patients with diabetes mellitus. Their
study showed that high brachial-ankle pulse wave velocity
(baPWV) was an independent risk factor for glaucoma in
diabetes mellitus patients [45]. Mean baPWV of the NTG
group was about 7.3% faster than that of the control group
[45]. However, mean baPWV of the POAG group was about
only 1.3% faster than that of the control group [45]. These
results suggested that arterial stiffness ismore associated with
NTG than with POAG [45]. If the underlying pathophysi-
ology of glaucoma is, at least partly, paravascular transport
blockage within the lamina cribrosa, it seems reasonable to
expect that systemic arterial stiffness may be a risk factor
for glaucoma since arterial hardening may also affect the
central retinal artery, resulting in impairment of the arterial
pulsation-driven “perivascular pump” in the eye.
The present hypothesis also fits with data on the associa-
tion between POAG and blood pressure. Pache and Flammer
reported hypotension, and in particular a nocturnal drop
in blood pressure, as an important risk factor for OAG
[46]. Furthermore, the Baltimore Eye Study showed an age-
related association between blood pressure and POAG [47].
In particular, systemic hypertension showed a protective
effect against glaucoma in younger patients, while it increased
the risk of glaucoma in older patients [47]. These age-
related findings could be explained by the assumption that
the optic nerve potentially benefits from the high perfusion
pressure accompanying relatively normal vessels early in life,
while chronic vascular changes that limit flow become the
dominant influence in older people with narrowed vessel
lumen [48]. However, these findings are also consistent
with the present glymphatic hypothesis of glaucoma. Indeed,
cerebrovascular pulsatility is dependent, at least in part, on
systemic blood pressure. Younger people with no blood vessel
damage yet may take advantage of high blood pressure by
increasing central retinal artery pulsatility, facilitating the
paravascular movement of CSF into the retina. However,
chronically elevated blood pressure may result in arterioscle-
rosis and as the blood vessels become rigidwith age, there will
be reduced central retinal artery pulsatility and subsequent
blockage of paravascular flow from the optic nerve to the
retina. In the case of nocturnal hypotension, decreased cen-
tral retinal artery pulsatility may lead to restriction of normal
glymphatic flow at the level of the lamina cribrosa during
sleep, when glymphatic clearance processes are maximal
[19].Therefore, nocturnal hypotension may have a magnified
negative effect on ocular glymphatic clearance compared to
hypotension during wakefulness.
Supportive evidence for the role of blood pressure in
paravascular flow comes from studies evaluating the role of
arterial pulsation in CSF-ISF exchange. The movement of
fluid in the perivascular spaces is caused by arterial pulsation
resulting from normal heart action [49]. Hadaczek et al.
[49] tested the hypothesis that the natural heartbeat could
contribute to the distribution and transport of intracranially
infused molecules within those spaces. The authors investi-
gated the movement of interstitially infused macromolecules
within the CNS in anesthetized rats with either high blood
pressure and heart rate (induced by epinephrine) or low
blood pressure and heart rate (induced by blood withdrawal)
and in rats euthanized just before the infusion (no heart
action) [49]. The rats with high blood pressure and heart
rate displayed a significantly larger distribution of the infused
molecules within the injected site and more extensive trans-
port of those molecules [49]. Their results confirmed a rapid
spread of molecules that cannot be explained by diffusion
as the sole mechanism [49]. As heart action contributed
substantially to broad distribution of the molecules, the
authors proposed that the pulse acts as a pump to distribute
particles infused into the interstitium of the brain along
the conduit of the perivascular space to sites deeper in the
parenchyma and remote in the brain [49]. In a more recent
study, Iliff et al. [20] used in vivo two-photon microscopy
in mice to visualize cerebral arterial wall pulsatility within
surrounding paravascular spaces. Systemic administration of
the adrenergic agonist dobutamine increased blood pressure
and heart rate [20]. A significant elevation in pulsatility was
observed along penetrating arteries [20]. In vivo and ex vivo
analysis of fluorescent CSF tracer influx into and through the
brain parenchyma demonstrated that increasing pulsatility
with dobutamine accelerated the rate of paravascular CSF
influx into brain tissue [20]. It is important to note that
arterial undulation depends on the expansion and contrac-
tion of the arterial wall with each pulse, which depends
not only on how much the heart contracts, but also on the
resistance of the circuit defined by diameter and elasticity of
the blood vessel [49]. With the onset of arteriosclerosis, the
artery walls become more rigid, the amplitude of pulsations
is reduced, and the passage of fluid along the blood vessel
walls is impaired [49]. Thus, regardless of blood pressure,
there may, under this circumstance, be no fluid flow outside
the blood vessel [49].The findings from the above-mentioned
animal studies are completely in line with the reported
association between blood pressure and POAG and therefore,
we speculate that the relationship between blood pressure
and paravascular flowmay be of importance when evaluating
the association between blood pressure and glaucomatous
damage. We hypothesize that restriction of normal glym-
phatic flow at the level of the lamina cribrosa may be a
new potential mechanism promoting the development of
glaucoma in patients with nocturnal hypotension and older
patients with systemic hypertension.
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3. Conclusions
The pathophysiology of POAG is still largely unknown,
although a joint contribution of vascular, biomechanical, and
biochemical factors is widely acknowledged, thus making
POAG rather a syndrome than a disease. Since glaucoma
is a leading cause of blindness in the world, exploring
its underlying pathophysiological mechanisms is extremely
important and challenging. Evidence from recent studies
appears supportive of the hypothesis that a “glymphatic
system” exists in the eye and optic nerve, analogous to the
described “glymphatic system” in the brain. As discussed
in the present paper, elucidation of a glymphatic clearance
pathway in the eye could provide a newunifying hypothesis of
glaucoma that can incorporate many aspects of the vascular,
biomechanical, and biochemical theories of the disease. We
are aware that the results from only a few studies until
now do not scientifically prove the existence of an “ocular
glymphatic system.” Much more study in the fields of eye
and glymphatic research is needed to validate this possibility.
Even though nothing conclusive can yet be said, these first
reports suggesting a paravascular transport system in the eye
and optic nerve are encouraging and, if confirmed, may offer
new perspectives for the development of novel diagnostic
and therapeutic strategies for this devastating disorder. We
therefore wish to encourage future research in this area.
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